Inferra AIResearch Tools

Inferra AI / Company / RGEN

Repligen Corp

RGEN · Health Care

Last earnings Oct 27, 2026

Key results

Revenuequarter

$189 million

Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises &#x2022

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Consumables and capital equipment revenues grew greater than 20%.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Both CDMO and biopharma revenues increased over 20%.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Reported revenuequarter

$189 million

• Reported revenue was $189 million compared to $155 million, an increase of 22% as reported, 18% organic.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Revenueytd

$540 million

Year-to-date 2025 revenue was $540 million compared to $467 million for the same period in 2024.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

GAAP net incomequarter

$15 million

• GAAP net income (loss) was $15 million, compared to ($1) million.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Adjusted net incomequarter

$26 million

Adjusted net income was $26 million compared to $24 million.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

EPSquarter

$0.46

Adjusted earnings per share was $0.46 on a fully diluted basis, compared to $0.43.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

AI analysis

Q3 2025 · reported Oct 28, 2025

Based on: Earnings release + parent 8-K — transcript not held

Revenue · Q3 2025
$189M
-59.5% -$278M vs year ago computed from stated figures
EX-99 · Oct 28, 2025
EPS · Q3 2025
$0.46
EX-99 · Oct 28, 2025
GAAP net income · Q3 2025
$15M
EX-99 · Oct 28, 2025
Reported revenue · Q3 2025
$189M
EX-99 · Oct 28, 2025

The quarter in charts

Revenue — quarterly

As stated

0167333500$467MSame quarter last year$189MQ3 2025

EX-99 · Oct 28, 2025 Statement values as stated in the release.

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Oct 28, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 2025Prior qtrYear ago
Revenue$189 million—$467 million
Reported revenue$189 million——
GAAP net income$15 million——
Adjusted net income$26 million——
EPS$0.46——

EX-99 · Oct 28, 2025

Guidance · company-stated

Direction: Raised

Revenue$189 million

“htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance • Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises • Orders increased sequentially and greater than 20% year-over-year • Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass.”

Revenue

““Given our year-to-date performance of 16% organic non-COVID revenue growth and our very strong Q3 orders, we are raising our full-year revenue guidance again.”

Midpoint vs latest-quarter revenue0.0%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs; restructuring charges including the costs of severance and accelerated depreciation among other charges; inventory step-up costs and adjustments; incremental costs attributed to CEO transition; contingent consideration related to the Company’s acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today’s webcast and conference call

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance • Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises • Orders increased sequentially and greater than 20% year-over-year • Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass.”

Revenue: ““Given our year-to-date performance of 16% organic non-COVID revenue growth and our very strong Q3 orders, we are raising our full-year revenue guidance again.”

Revenue — Raised (“increase”)
“htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance • Revenue of $189 million, year-over-year increase of 22% as reported and 18% organic with double-digit reported growth across all franchises • Orders increased sequentially and greater than 20% year-over-year • Increasing revenue guidance to a range of $729 to $737 million, which represents 14% -15.5% year-over-year non-COVID organic growth WALTHAM, Mass.”

Revenue — Raised (“raising”)
““Given our year-to-date performance of 16% organic non-COVID revenue growth and our very strong Q3 orders, we are raising our full-year revenue guidance again.”

Classified from the release's primary full-year outlook statement.

Capital allocation

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs; restructuring charges including the costs of severance and accelerated depreciation among other charges; inventory step-up costs and adjustments; incremental costs attributed to CEO transition; contingent consideration related to the Company’s acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Strategy & priorities

, October 28, 2025 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

We announced a strategic partnership with Novasign to develop and integrate Novasign’s digital twin capabilities into Repligen filtration systems.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Risks & headwinds

Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.

SEC original ↗Repligen Corp — Earnings release (8-K exhibit)EX-99Oct 28, 2025

Documents

Earnings deck slides

0 decks with slide view

Repligen Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Repligen Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

31 documents

Earnings releases

16 documents

Presentations

2 documents

Transcripts

0 documents

No transcripts for Repligen Corp are held in this edition of the library.

Mentioned by

7 companies

Other tracked companies whose held documents mention Repligen Corp by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.